Stock Events

Stock Events

ZyVersa Therapeutics 

$0.103000
22
+$0.00+3.83% 17:42 Today

Statistics

Day High
0.099
Day Low
0.099
52W High
0.3
52W Low
0.077
Volume
2,400
Avg. Volume
11,960
Mkt Cap
833,888
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
Next
-2.73
-1.22
0.29
1.79
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-24.95MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZVSA. It's not an investment recommendation.
Intuitive Machines
4
LUNR
Coca-Cola
3
KO
SPDR S&P 500 Trust
3
SPY
Rocket Lab
3
RKLB

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on creating new treatments for inflammatory diseases, directly competing with ZyVersa's inflammatory disease segment.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals develops therapies for inflammatory conditions, overlapping with ZyVersa's product pipeline.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in the development of treatments for inflammatory and renal diseases, areas ZyVersa is targeting.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a diverse portfolio in immunology and inflammatory diseases, competing with ZyVersa's therapeutic areas.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on innovative therapeutics for inflammatory diseases places it in direct competition with ZyVersa.
Biogen
BIIB
Mkt Cap32.28B
Biogen's investment in novel therapies for neurological and inflammatory diseases makes it a competitor.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the inflammatory disease space.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of products for inflammatory conditions, directly competing with ZyVersa's focus areas.
Novartis
NVS
Mkt Cap292.35B
Novartis AG engages in the research, development, and marketing of healthcare products, including treatments for inflammatory diseases.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in various therapeutic areas, including inflammation, competing with ZyVersa's development programs.

About

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Show more...
CEO
Stephen C. Glover
Employees
6
Country
United States
ISIN
US98987D3008

Listings

OTC Link
US
ZVSA

0 Comments

Share your thoughts

FAQ

What is ZyVersa Therapeutics stock price today?▼
The current price of ZVSA is $0.10 USD — it has increased by +3.83% in the past 24 hours. Watch ZyVersa Therapeutics stock price performance more closely on the chart.
What is ZyVersa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange ZyVersa Therapeutics stocks are traded under the ticker ZVSA.
Is ZyVersa Therapeutics stock price growing?▼
ZVSA stock has risen by +4.04% compared to the previous week, the month change is a +3% rise, over the last year ZyVersa Therapeutics has showed a -27.46% decrease.
What is ZyVersa Therapeutics market cap?▼
Today ZyVersa Therapeutics has the market capitalization of 833,888
When is the next ZyVersa Therapeutics earnings date?▼
ZyVersa Therapeutics is going to release the next earnings report on November 18, 2026.
What is ZyVersa Therapeutics revenue for the last year?▼
ZyVersa Therapeutics revenue for the last year amounts to 0 USD.
What is ZyVersa Therapeutics net income for the last year?▼
ZVSA net income for the last year is -24.95M USD.
How many employees does ZyVersa Therapeutics have?▼
As of September 04, 2026, the company has 6 employees.
In which sector is ZyVersa Therapeutics located?▼
ZyVersa Therapeutics operates in the Health & Wellness sector.
When did ZyVersa Therapeutics complete a stock split?▼
The last stock split for ZyVersa Therapeutics was on April 26, 2024 with a ratio of 1:10.
Where is ZyVersa Therapeutics headquartered?▼
ZyVersa Therapeutics is headquartered in Weston, United States.